<?xml version="1.0" encoding="UTF-8"?>
<p>Secondary virologic endpoints included time to cessation of viral shedding by virus titer and change from baseline in influenza virus titer.
 <sup>
  <xref rid="R23" ref-type="bibr">23</xref>
 </sup> Exploratory virologic endpoints included frequency of treatment-emergent amino acid substitutions (using Sanger sequencing).
 <sup>
  <xref rid="R24" ref-type="bibr">24</xref>
 </sup> Baseline samples from both treatment groups were also tested for coinfections (viral and bacterial pathogens), using the BioFire FilmArray Respiratory Panel 2 assay.
 <sup>
  <xref rid="R25" ref-type="bibr">25</xref>
 </sup>
</p>
